[1]
Miners, J.O.; Yang, X.; Knights, K.M.; Zhang, L. The role of the kidney in drug elimination: Transport, metabolism, and the impact of kidney disease on drug clearance. Clin. Pharmacol. Ther., 2017, 102(3), 436-449.
[2]
Nolin, T.D.; Naud, J.; Leblond, F.A.; Pichette, V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther., 2008, 83(6), 898-903.
[3]
Hall, B.E.; Willett, F.M.; Feichtmeir, T.V.; Reed, E.B.; Dowling, W.F. Current trends in cancer chemotherapy. Calif. Med., 1956, 84(1), 1-9.
[4]
Lyman, G.H. Impact of chemotherapy dose intensity on cancer patient outcomes. J. Natl. Compr. Canc. Netw., 2009, 7(1), 99-108.
[5]
Gilman, A. The initial clinical trial of nitrogen mustard. Am. J. Surg., 1963, 105, 574-578.
[6]
Fujita, K.I.; Ishida, H.; Kubota, Y.; Sasaki, Y. Toxicities of receptor tyrosine kinase inhibitors in cancer pharmacotherapy: Management with clinical pharmacology. Curr. Drug Metab., 2017, 18(3), 186-198.
[7]
Dienstmann, R.; Brana, I.; Rodon, J.; Tabernero, J. Toxicity as a biomarker of efficacy of molecular targeted therapies: Focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist, 2011, 16(12), 1729-1740.
[8]
De Wit, D.; Guchelaar, H.J.; Den Hartigh, J.; Gelderblom, H.; Van Erp, N.P. Individualized dosing of tyrosine kinase inhibitors: Are we there yet? Drug Discov. Today, 2015, 20(1), 18-36.
[9]
Kim, I.W.; Yun, H.Y.; Choi, B.; Han, N.; Kim, M.G.; Park, S.; Oh, J.M. Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. Eur. J. Clin. Pharmacol., 2013, 69(8), 1543-1551.
[10]
Chang, T.K.; Weber, G.F.; Crespi, C.L.; Waxman, D.J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res., 1993, 53(23), 5629-5637.
[11]
Roy, P.; Yu, L.J.; Crespi, C.L.; Waxman, D.J. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab. Dispos., 1999, 27(6), 655-666.
[12]
Dimeloe, S.; Frick, C.; Fischer, M.; Gubser, P.M.; Razik, L.; Bantug, G.R.; Ravon, M.; Langenkamp, A.; Hess, C. Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis. Eur. J. Immunol., 2014, 44(12), 3614-3620.
[13]
Marre, F.; Sanderink, G.J.; De Sousa, G.; Gaillard, C.; Martinet, M.; Rahmani, R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res., 1996, 56(6), 1296-1302.
[14]
Baker, S.D.; Verweij, J.; Cusatis, G.A.; Van Schaik, R.H.; Marsh, S.; Orwick, S.J.; Franke, R.M.; Hu, S. Schuetz, E.G.; Lamba, V.; Messersmith, W.A.; Wolff, A.C.; Carducci, M.A.; Sparreboom, A. Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther., 2009, 85(2), 155-163.
[15]
De Graan, A.J.; Lancaster, C.S.; Obaidat, A.; Hagenbuch, B.; Elens, L.; Friberg, L.E.; De Bruijn, P.; Hu, S.; Gibson, A.A.; Bruun, G.H.; Corydon, T.J.; Mikkelsen, T.S.; Walker, A.L.; Du, G.; Loos, W.J.; van Schaik, R.H.; Baker, S.D.; Mathijssen, R.H.; Sparreboom, A. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin. Cancer Res., 2012, 18(16), 4433-4440.
[16]
Lal, S.; Wong, Z.W.; Sandanaraj, E.; Xiang, X.; Ang, P.C.; Lee, E.J.; Chowbay, B. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci., 2008, 99(4), 816-823.
[17]
Mross, K.; Maessen, P.; Van Der Vijgh, W.J.; Gall, H.; Boven, E.; Pinedo, H.M. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J. Clin. Oncol., 1988, 6(3), 517-526.
[18]
Piska, K.; Koczurkiewicz, P.; Bucki, A.; Wojcik-Pszczola, K.; Kolaczkowski, M.; Pekala, E. Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents. Invest. New Drugs, 2017, 35(3), 375-385.
[19]
Salvatorelli, E.; Guarnieri, S.; Menna, P.; Liberi, G.; Calafiore, A.M.; Mariggio, M.A.; Mordente, A.; Gianni, L.; Minotti, G. Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. J. Biol. Chem., 2006, 281(16), 10990-11001.
[20]
Robey, R.W.; Honjo, Y.; Morisaki, K.; Nadjem, T.A.; Runge, S.; Risbood, M.; Poruchynsky, M.S.; Bates, S.E. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer, 2003, 89(10), 1971-1978.
[21]
Swami, U.; Chaudhary, I.; Ghalib, M.H.; Goel, S. Eribulin - a review of preclinical and clinical studies. Crit. Rev. Oncol. Hematol., 2012, 81(2), 163-184.
[22]
Cui, Y.; Konig, J.; Buchholz, J.K.; Spring, H.; Leier, I.; Keppler, D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol., 1999, 55(5), 929-937.
[23]
Kool, M.; Van Der Linden, M.; De Haas, M.; Scheffer, G.L.; De Vree, J.M.; Smith, A.J.; Jansen, G.; Peters, G.J.; Ponne, N.; Scheper, R.J.; Elferink, R.P.; Baas, F.; Borst, P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA, 1999, 96(12), 6914-6919.
[24]
Eddabra, L.; Wenner, T.; El Btaouri, H.; Baranek, T.; Madoulet, C.; Cornillet-Lefebvre, P.; Morjani, H. Arginine 482 to glycine mutation in ABCG2/BCRP increases etoposide transport and resistance to the drug in HEK-293 cells. Oncol. Rep., 2012, 27(1), 232-237.
[25]
Yang, Z.; Wu, D.; Bui, T.; Ho, R.J. A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J. Pharmacol. Exp. Ther., 2008, 327(2), 474-481.
[26]
Mathijssen, R.H.; Marsh, S.; Karlsson, M.O.; Xie, R.; Baker, S.D.; Verweij, J.; Sparreboom, A.; McLeod, H.L. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res., 2003, 9(9), 3246-3253.
[27]
Mathijssen, R.H.; Van Alphen, R.J.; Verweij, J.; Loos, W.J.; Nooter, K.; Stoter, G.; Sparreboom, A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res., 2001, 7(8), 2182-2194.
[28]
Fujita, K.; Sugiura, T.; Okumura, H.; Umeda, S.; Nakamichi, N.; Watanabe, Y.; Suzuki, H.; Sunakawa, Y.; Shimada, K.; Kawara, K.; Sasaki, Y.; Kato, Y. Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm. Res., 2014, 31(1), 204-215.
[29]
Cresteil, T.; Monsarrat, B.; Alvinerie, P.; Treluyer, J.M.; Vieira, I.; Wright, M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res., 1994, 54(2), 386-392.
[30]
Rahman, A.; Korzekwa, K.R.; Grogan, J.; Gonzalez, F.J.; Harris, J.W. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res., 1994, 54(21), 5543-5546.
[31]
Smith, N.F.; Marsh, S.; Scott-Horton, T.J.; Hamada, A.; Mielke, S.; Mross, K.; Figg, W.D.; Verweij, J.; McLeod, H.L.; Sparreboom, A. Variants in the SLCO1B3 gene: Interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther., 2007, 81(1), 76-82.
[32]
Nieuweboer, A.J.; Hu, S.; Gui, C.; Hagenbuch, B.; Ghobadi Moghaddam-Helmantel, I.M.; Gibson, A.A.; De Bruijn, P.; Mathijssen, R.H.; Sparreboom, A. Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res., 2014, 74(11), 3137-3145.
[33]
Sparreboom, A.; Van Asperen, J.; Mayer, U.; Schinkel, A.H.; Smit, J.W.; Meijer, D.K.; Borst, P.; Nooijen, W.J.; Beijnen, J.H.; Van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA, 1997, 94(5), 2031-2035.
[34]
Beulz-Riche, D.; Grude, P.; Puozzo, C.; Sautel, F.; Filaquier, C.; Riche, C.; Ratanasavanh, D. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam. Clin. Pharmacol., 2005, 19(5), 545-553.
[35]
Kajita, J.; Kuwabara, T.; Kobayashi, H.; Kobayashi, S. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab. Dispos., 2000, 28(9), 1121-1127.
[36]
Lagas, J.S.; Damen, C.W.; Van Waterschoot, R.A.; Iusuf, D.; Beijnen, J.H.; Schinkel, A.H. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine. Mol. Pharmacol., 2012, 82(4), 636-644.
[37]
Wong, M.; Balleine, R.L.; Blair, E.Y.; McLachlan, A.J.; Ackland, S.P.; Garg, M.B.; Evans, S.; Farlow, D.; Collins, M.; Rivory, L.P.; Hoskins, J.M.; Mann, G.J.; Clarke, C.L.; Gurney, H. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J. Clin. Oncol., 2006, 24(16), 2448-2455.
[38]
Van Hoppe, S.; Schinkel, A.H. What next? Preferably development of drugs that are no longer transported by the ABCB1 and ABCG2 efflux transporters. Pharmacol. Res., 2017, 123, 144.
[39]
Stopfer, P.; Marzin, K.; Narjes, H.; Gansser, D.; Shahidi, M.; Uttereuther-Fischer, M.; Ebner, T. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother. Pharmacol., 2012, 69(4), 1051-1061.
[40]
Li, J.; Zhao, M.; He, P.; Hidalgo, M.; Baker, S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res., 2007, 13(12), 3731-3737.
[41]
Marchetti, S.; De Vries, N.A.; Buckle, T.; Bolijn, M.J.; Van Eijndhoven, M.A.; Beijnen, J.H.; Mazzanti, R.; Van Tellingen, O.; Schellens, J.H. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol. Cancer Ther., 2008, 7(8), 2280-2287.
[42]
Zimmerman, E.I.; Hu, S.; Roberts, J.L.; Gibson, A.A.; Orwick, S.J.; Li, L.; Sparreboom, A.; Baker, S.D. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin. Cancer Res., 2013, 19(6), 1458-1466.
[43]
Castellino, S.; O’Mara, M.; Koch, K.; Borts, D.J.; Bowers, G.D.; MacLauchlin, C. Human metabolism of lapatinib, a dual kinase inhibitor: Implications for hepatotoxicity. Drug Metab. Dispos., 2012, 40(1), 139-150.
[44]
Polli, J.W.; Humphreys, J.E.; Harmon, K.A.; Castellino, S.; O’Mara, M.J.; Olson, K.L.; John-Williams, L.S.; Koch, K.M.; Serabjit-Singh, C.J. The role of efflux and uptake transporters in [N-3-chloro-4-[(3-fluorobenzyl)oxy]phenyl-6-[5-([2-(methylsulfonyl)ethyl]amino methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos., 2008, 36(4), 695-701.
[45]
Dickinson, P.A.; Cantarini, M.V.; Collier, J.; Frewer, P.; Martin, S.; Pickup, K.; Ballard, P. Metabolic disposition of osimertinib in rats, dogs, and humans: Insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab. Dispos., 2016, 44(8), 1201-1212.
[46]
MacLeod, A.K. Lin; Huang, J.T.; McLaughlin, L.A.; Henderson, C.J.; Wolf, C.R. Identification of novel pathways of osimertinib disposition and potential implications for the outcome of lung cancer therapy. Clin. Cancer Res., 2018, 24(9), 2138-2147.
[47]
Zientek, M.A.; Goosen, T.C.; Tseng, E.; Lin, J.; Bauman, J.N.; Walker, G.S.; Kang, P.; Jiang, Y.; Freiwald, S.; Neul, D.; Smith, B.J. In vitro kinetic characterization of axitinib metabolism. Drug Metab. Dispos., 2016, 44(1), 102-114.
[48]
Chen, Y.; Tortorici, M.A.; Garrett, M.; Hee, B.; Klamerus, K.J.; Pithavala, Y.K. Clinical pharmacology of axitinib. Clin. Pharmacokinet., 2013, 52(9), 713-725.
[49]
Poller, B.; Iusuf, D.; Sparidans, R.W.; Wagenaar, E.; Beijnen, J.H.; Schinkel, A.H. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab. Dispos., 2011, 39(5), 729-735.
[50]
Shumaker, R.C.; Aluri, J.; Fan, J.; Martinez, G.; Thompson, G.A.; Ren, M. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin. Drug Investig., 2014, 34(9), 651-659.
[51]
Verheijen, R.B.; Beijnen, J.H.; Schellens, J.H.M.; Huitema, A.D.R.; Steeghs, N. Clinical pharmacokinetics and pharmacodynamics of pazopanib: Towards optimized dosing. Clin. Pharmacokinet., 2017, 56(9), 987-997.
[52]
Nieto, M.; Borregaard, J.; Ersboll, J.; ten Bosch, G.J.; Van Zwieten-Boot, B.; Abadie, E.; Schellens, J.H.; Pignatti, F. The european medicines agency review of pazopanib for the treatment of advanced renal cell carcinoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Clin. Cancer Res., 2011, 17(21), 6608-6614.
[53]
Ellawatty, W.E.A.; Masuo, Y.; Fujita, K.I.; Yamazaki, E.; Ishida, H.; Arakawa, H.; Nakamichi, N.; Abdelwahed, R.; Sasaki, Y.; Kato, Y. Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib. Drug Metab. Dispos., 2018, 46(1), 33-40.
[54]
Ohya, H.; Shibayama, Y.; Ogura, J.; Narumi, K.; Kobayashi, M.; Iseki, K. Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol. Pharm. Bull., 2015, 38(4), 582-586.
[55]
Fujita, K.I.; Masuo, Y.; Yamazaki, E.; Shibutani, T.; Kubota, Y.; Nakamichi, N.; Sasaki, Y.; Kato, Y. Involvement of the transporters P-glycoprotein and breast cancer resistance protein in dermal distribution of the multikinase inhibitor regorafenib and its active metabolites. J. Pharm. Sci., 2017, 106(9), 2632-2641.
[56]
Lathia, C.; Lettieri, J.; Cihon, F.; Gallentine, M.; Radtke, M.; Sundaresan, P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother. Pharmacol., 2006, 57(5), 685-692.
[57]
Vasilyeva, A.; Durmus, S.; Li, L.; Wagenaar, E.; Hu, S.; Gibson, A.A.; Panetta, J.C.; Mani, S.; Sparreboom, A.; Baker, S.D.; Schinkel, A.H. Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Res., 2015, 75(13), 2729-2736.
[58]
Hu, S.; Chen, Z.; Franke, R.; Orwick, S.; Zhao, M.; Rudek, M.A.; Sparreboom, A.; Baker, S.D. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin. Cancer Res., 2009, 15(19), 6062-6069.
[59]
Poller, B.; Wagenaar, E.; Tang, S.C.; Schinkel, A.H. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol. Pharm., 2011, 8(2), 571-582.
[60]
Amaya, G.M.; Durandis, R.; Bourgeois, D.S.; Perkins, J.A.; Abouda, A.A.; Wines, K.J.; Mohamud, M.; Starks, S.A.; Daniels, R.N.; Jackson, K.D. Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib. Chem. Res. Toxicol., 2018, 31(7), 570-584.
[61]
Thornton, K.; Kim, G.; Maher, V.E.; Chattopadhyay, S.; Tang, S.; Moon, Y.J.; Song, P.; Marathe, A.; Balakrishnan, S.; Zhu, H.; Garnett, C.; Liu, Q.; Booth, B.; Gehrke, B.; Dorsam, R.; Verbois, L.; Ghosh, D.; Wilson, W.; Duan, J.; Sarker, H.; Miksinski, S.P.; Skarupa, L.; Ibrahim, A.; Justice, R.; Murgo, A.; Pazdur, R. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin. Cancer Res., 2012, 18(14), 3722-3730.
[62]
Khurana, V.; Minocha, M.; Pal, D.; Mitra, A.K. Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. Drug Metabol. Drug Interact., 2014, 29(3), 179-190.
[63]
Nakagawa, T.; Fowler, S.; Takanashi, K.; Youdim, K.; Yamauchi, T.; Kawashima, K.; Sato-Nakai, M.; Yu, L.; Ishigai, M. In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: Contribution of CYP3A enzymes. Xenobiotica, 2018, 48(6), 546-554.
[64]
Nix, N.M.; Brown, K.S. Ceritinib for ALK-rearrangement-positive non-small cell lung cancer. J. Adv. Pract. Oncol., 2015, 6(2), 156-160.
[65]
Kort, A.; Sparidans, R.W.; Wagenaar, E.; Beijnen, J.H.; Schinkel, A.H. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacol. Res., 2015, 102, 200-207.
[66]
Fujiwara, Y.; Hamada, A.; Mizugaki, H.; Aikawa, H.; Hata, T.; Horinouchi, H.; Kanda, S.; Goto, Y.; Itahashi, K.; Nokihara, H.; Yamamoto, N.; Ohe, Y. Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism. Cancer Sci., 2016, 107(8), 1117-1123.
[67]
Tang, S.C.; Nguyen, L.N.; Sparidans, R.W.; Wagenaar, E.; Beijnen, J.H.; Schinkel, A.H. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int. J. Cancer, 2014, 134(6), 1484-1494.
[68]
Haubitz, M.; Bohnenstengel, F.; Brunkhorst, R.; Schwab, M.; Hofmann, U.; Busse, D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int., 2002, 61(4), 1495-1501.
[70]
Yang, L.; Zhang, X.C.; Yu, S.F.; Zhu, H.Q.; Hu, A.P.; Chen, J.; Shen, P. Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: A case report. BMC Cancer, 2015, 15, 917.
[71]
Ekhart, C.; Kerst, J.M.; Rodenhuis, S.; Beijnen, J.H.; Huitema, A.D. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. Cancer Chemother. Pharmacol., 2009, 63(2), 375-379.
[72]
Kaneda, H.; Okamoto, I.; Nakagawa, K. Pharmacokinetics of docetaxel in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis. J. Thorac. Oncol., 2012, 7(3), 621-622.
[73]
Dimopoulos, M.A.; Deliveliotis, C.; Moulopoulos, L.A.; Papadimitriou, C.; Mitropoulos, D.; Anagnostopoulos, A.; Athanassiades, P.; Dimopoulos, C. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology, 1998, 52(1), 56-60.
[74]
Yoshida, H.; Goto, M.; Honda, A.; Nabeshima, T.; Kumazawa, T.; Inagaki, J.; Yamanaka, N.; Ota, K. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis. Cancer Chemother. Pharmacol., 1994, 33(6), 450-454.
[75]
Li, Y.F.; Fu, S.; Hu, W.; Liu, J.H.; Finkel, K.W.; Gershenson, D.M.; Kavanagh, J.J. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int. J. Gynecol. Cancer, 2007, 17(4), 739-763.
[76]
Galsky, M.D.; Iasonos, A.; Mironov, S.; Scattergood, J.; Boyle, M.G.; Bajorin, D.F. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer, 2007, 109(3), 549-555.
[77]
Li, Y.; Finkel, K.W.; Hu, W.; Fu, S.; Liu, J.; Coleman, R.; Kavanagh, J.J. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol. Oncol., 2007, 106(2), 375-380.
[78]
Gori, S.; Rulli, A.; Mosconi, A.M.; Sidoni, A.; Colozza, M.; Crino, L. Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment. Tumori, 2006, 92(4), 364-365.
[79]
Tan, A.R.; Sarantopoulos, J.; Lee, L.; Reyderman, L.; He, Y.; Olivo, M.; Goel, S. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function. Cancer Chemother. Pharmacol., 2015, 76(5), 1051-1061.
[81]
D’Incalci, M.; Rossi, C.; Zucchetti, M.; Urso, R.; Cavalli, F.; Mangioni, C.; Willems, Y.; Sessa, C. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res., 1986, 46(5), 2566-2571.
[83]
Takezawa, K.; Okamoto, I.; Fukuoka, M.; Nakagawa, K. Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. J. Thorac. Oncol., 2008, 3(9), 1073-1075.
[84]
Suzuki, S.; Koide, M.; Sakamoto, S.; Matsuo, T. Pharmacokinetics of carboplatin and etoposide in a haemodialysis patient with Merkel-cell carcinoma. Nephrol. Dial. Transplant., 1997, 12(1), 137-140.
[85]
Watanabe, R.; Takiguchi, Y.; Moriya, T.; Oda, S.; Kurosu, K.; Tanabe, N.; Tatsumi, K.; Nagao, K.; Kuriyama, T. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. Br. J. Cancer, 2003, 88(1), 25-30.
[86]
Inoue, A. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann. Oncol., 2004, 15(1), 51-54.
[87]
Yeung, C.K.; Shen, D.D.; Thummel, K.E.; Himmelfarb, J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int., 2014, 85(3), 522-528.
[88]
Fleming, G.F. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann. Oncol., 2003, 14(7), 1142-1147.
[89]
Rengelshausen, J.; Hull, W.E.; Schwenger, V.; Göggelmann, C.; Walter-Sack, I.; Bommer, J. Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. Am. J. Kidney Dis., 2002, 39(2), e10.11-e10.17.
[90]
Gusella, M.; Rebeschini, M.; Cartei, G.; Ferrazzi, E.; Ferrari, M.; Padrini, R. Effect of hemodialysis on the metabolic clearance of 5-fluorouracil in a patient with end-stage renal failure. Ther. Drug Monit., 2005, 27(6), 816-818.
[91]
Fujita, K.; Sunakawa, Y.; Miwa, K.; Akiyama, Y.; Sugiyama, M.; Kawara, K.; Ishida, H.; Yamashita, K.; Mizuno, K.; Saji, S.; Ichikawa, W.; Yamamoto, W.; Nagashima, F.; Miya, T.; Narabayashi, M.; Ando, Y.; Hirose, T.; Sasaki, Y. Delayed elimination of SN-38 in cancer patients with severe renal failure. Drug Metab. Dispos., 2011, 39(2), 161-164.
[92]
Fujita, K.; Masuo, Y.; Okumura, H.; Watanabe, Y.; Suzuki, H.; Sunakawa, Y.; Shimada, K.; Kawara, K.; Akiyama, Y.; Kitamura, M.; Kunishima, M.; Sasaki, Y.; Kato, Y. Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. Pharm. Res., 2016, 33(2), 269-282.
[93]
Kehrer, D.F.; Yamamoto, W.; Verweij, J.; de Jonge, M.J.; de Bruijn, P.; Sparreboom, A. Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies. Clin. Cancer Res., 2000, 6(9), 3451-3458.
[94]
Czock, D.; Rasche, F.M.; Boesler, B.; Shipkova, M.; Keller, F. Irinotecan in cancer patients with end-stage renal failure. Ann. Pharmacother., 2009, 43(2), 363-369.
[95]
De Jong, F.A.; Van Der Bol, J.M.; Mathijssen, R.H.; Van Gelder, T.; Wiemer, E.A.; Sparreboom, A.; Verweij, J. Renal function as a predictor of irinotecan-induced neutropenia. Clin. Pharmacol. Ther., 2008, 84(2), 254-262.
[96]
Venook, A.P. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann. Oncol., 2003, 14(12), 1783-1790.
[97]
Gelderblom, H.; Verweij, J.; Brouwer, E.; Pillay, M.; De Bruijn, P.; Nooter, K.; Stoter, G.; Sparreboom, A. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. Drug Metab. Dispos., 1999, 27(11), 1300-1305.
[98]
Heijns, J.B.; van der Burg, M.E.; van Gelder, T.; Fieren, M.W.; De Bruijn, P.; Van Der Gaast, A.; Loos, W.J. Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment. Cancer Chemother. Pharmacol., 2008, 62(5), 841-847.
[99]
Kodama, J.; Sasaki, A.; Masahiro, S.; Seki, N.; Kusumoto, T.; Nakamura, K.; Hongo, A.; Hiramatsu, Y. Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. Oncol. Lett., 2010, 1(3), 511-513.
[100]
Baur, M.; Fazeny-Doerner, B.; Olsen, S.J.; Dittrich, C. High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: A case report with pharmacokinetic analysis and review of the literature. Int. J. Gynecol. Cancer, 2008, 18(3), 564-570.
[101]
Watanabe, M.; Aoki, Y.; Tomita, M.; Sato, T.; Takaki, Y.; Kato, N.; Kikuchi, M.; Kase, H.; Tanaka, K. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol. Oncol., 2002, 84(2), 335-338.
[102]
Kawate, S.; Takeyoshi, I.; Morishita, Y. Pharmacokinetics of paclitaxel in a hemodialysis patient with advanced gastric cancer: A case report. World J. Gastroenterol., 2006, 12(32), 5237-5239.
[103]
Kanematsu, K.; Tsujimoto, H.; Nomura, S.; Horiguchi, H.; Ito, N.; Yamazaki, K.; Hiraki, S.; Aosasa, S.; Yamamoto, J.; Hase, K. Weekly paclitaxel therapy for gastric cancer in patients with renal dysfunction: A case report. Ann. Med. Surg. (Lond.), 2016, 11, 26-28.
[104]
Rollino, C.; Milongo, R.; Schaerer, R.; Cordonnier, D. Vinorelbine therapy in a hemodialyzed patient. Nephron, 1992, 61(2), 232-233.
[105]
Wiebe, S.; Schnell, D.; Kulzer, R.; Gansser, D.; Weber, A.; Wallenstein, G.; Halabi, A.; Conrad, A.; Wind, S. Influence of renal impairment on the pharmacokinetics of afatinib: An open-label, single-dose study. Eur. J. Drug Metab. Pharmacokinet., 2017, 42(3), 461-469.
[106]
Bersanelli, M.; Tiseo, M.; Artioli, F.; Lucchi, L.; Ardizzoni, A. Gefitinib and afatinib treatment in an advanced Non-small Cell Lung Cancer (NSCLC) patient undergoing hemodialysis. Anticancer Res., 2014, 34(6), 3185-3188.
[107]
Miller, A.A.; Murry, D.J.; Owzar, K.; Hollis, D.R.; Lewis, L.D.; Kindler, H.L.; Marshall, J.L.; Villalona-Calero, M.A.; Edelman, M.J.; Hohl, R.J.; Lichtman, S.M.; Ratain, M.J. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J. Clin. Oncol., 2007, 25(21), 3055-3060.
[108]
Togashi, Y.; Masago, K.; Fukudo, M.; Terada, T.; Ikemi, Y.; Kim, Y.H.; Fujita, S.; Irisa, K.; Sakamori, Y.; Mio, T.; Inui, K.; Mishima, M. Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J. Thorac. Oncol., 2010, 5(5), 601-605.
[109]
Gridelli, C.; Maione, P.; Galetta, D.; Rossi, A. Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure. J. Thorac. Oncol., 2007, 2(1), 96-98.
[110]
Rossi, A.; Maione, P.; Del Gaizo, F.; Guerriero, C.; Castaldo, V.; Gridelli, C. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: Two clinical cases. Lung Cancer, 2005, 47(3), 421-423.
[111]
Shinagawa, N.; Yamazaki, K.; Asahina, H.; Agata, J.; Itoh, T.; Nishimura, M. Gefitinib administration in a patient with lung cancer undergoing hemodialysis. Lung Cancer, 2007, 58(3), 422-424.
[112]
Tamura, T.; Takagi, Y.; Okubo, H.; Yamaguchi, S.; Kikkawa, Y.; Hashimoto, I.; Kaburagi, T.; Miura, M.; Satoh, H.; Hizawa, N. Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis. Lung Cancer, 2017, 112, 225-226.
[113]
Yamada, H.; Satoh, H.; Hida, N.; Nakaizumi, T.; Terashima, H.; Hizawa, N. Osimertinib for an older de novo T790M patient with chronic kidney disease. Geriatr. Gerontol. Int., 2018, 18(3), 503-504.
[115]
Thiery-Vuillemin, A.; Orillard, E.; Mouillet, G.; Calcagno, F.; Devillard, N.; Bouchet, S.; Royer, B. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma. Cancer Chemother. Pharmacol., 2017, 79(6), 1273-1276.
[116]
Nguyen, L.; Holland, J.; Ramies, D.; Mamelok, R.; Benrimoh, N.; Ciric, S.; Marbury, T.; Preston, R.A.; Heuman, D.M.; Gavis, E.; Lacy, S. Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J. Clin. Pharmacol., 2016, 56(9), 1130-1140.
[118]
Masini, C.; Vitale, M.G.; Maruzzo, M.; Procopio, G.; De Giorgi, U.; Buti, S.; Rossetti, S.; Iacovelli, R.; Atzori, F.; Cosmai, L.; Vignani, F.; Prati, G.; Scagliarini, S.; Guida, A.; Berselli, A.; Pinto, C. Safety and efficacy of pazopanib in first-line metastatic renal-cell carcinoma with or without renal failure: CORE-URO-01 study. Clin. Genitourin. Cancer, 2019, 17(1), e150-e155.
[119]
Shetty, A.V.; Matrana, M.R.; Atkinson, B.J.; Flaherty, A.L.; Jonasch, E.; Tannir, N.M. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clin. Genitourin. Cancer, 2014, 12(5), 348-353.
[120]
Czarnecka, A.M.; Kawecki, M.; Lian, F.; Korniluk, J.; Szczylik, C. Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. Future Oncol., 2015, 11(16), 2267-2282.
[121]
Bersanelli, M.; Facchinetti, F.; Tiseo, M.; Maiorana, M.; Buti, S. Pazopanib in renal cell carcinoma dialysis patients: A mini-review and a case report. Curr. Drug Targets, 2016, 17(15), 1755-1760.
[123]
Miller, A.A.; Murry, D.J.; Owzar, K.; Hollis, D.R.; Kennedy, E.B.; Abou-Alfa, G.; Desai, A.; Hwang, J.; Villalona-Calero, M.A.; Dees, E.C.; Lewis, L.D.; Fakih, M.G.; Edelman, M.J.; Millard, F.; Frank, R.C.; Hohl, R.J.; Ratain, M.J. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J. Clin. Oncol., 2009, 27(11), 1800-1805.
[124]
Kennoki, T.; Kondo, T.; Kimata, N.; Murakami, J.; Ishimori, I.; Nakazawa, H.; Hashimoto, Y.; Kobayashi, H.; Iizuka, J.; Takagi, T.; Yoshida, K.; Tanabe, K. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn. J. Clin. Oncol., 2011, 41(5), 647-655.
[125]
Ishii, T.; Hatano, E.; Taura, K.; Mizuno, T.; Kawai, T.; Fukudo, M.; Katsura, T.; Uemoto, S. Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic study. Hepatol. Res., 2014, 44(6), 685-688.
[126]
Shinsako, K.; Mizuno, T.; Terada, T.; Watanabe, J.; Kamba, T.; Nakamura, E.; Ogawa, O.; Inui, K. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: A case study. Int. J. Clin. Oncol., 2010, 15(5), 512-514.
[127]
Castagneto, B.; Stevani, I.; Giorcelli, L.; Montefiore, F.; Bigatti, G.L.; Pisacco, P.; Cosimi, M.F. Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: A case report. Med. Oncol., 2011, 28(4), 1384-1388.
[128]
Omae, K.; Kondo, T.; Kennoki, T.; Takagi, T.; Iizuka, J.; Kobayashi, H.; Hashimoto, Y.; Tanabe, K. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. Int. J. Clin. Oncol., 2016, 21(1), 126-132.
[129]
Ferraris, E.; Di Cesare, P.; Lasagna, A.; Paglino, C.; Imarisio, I.; Porta, C. Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. Tumori, 2009, 95(4), 542-544.
[130]
Ruppin, S.; Protzel, C.; Klebingat, K.J.; Hakenberg, O.W. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. Eur. Urol., 2009, 55(4), 986-988.
[131]
Parsa, V.; Heilbrun, L.; Smith, D.; Sethi, A.; Vaishampayan, U. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin. Genitourin. Cancer, 2009, 7(2), E10-E15.
[132]
Tatsugami, K.; Oya, M.; Kabu, K.; Akaza, H. Efficacy and safety of sorafenib for advanced renal cell carcinoma: Real-world data of patients with renal impairment. Oncotarget, 2018, 9(27), 19406-19414.
[134]
Khosravan, R.; Toh, M.; Garrett, M.; La Fargue, J.; Ni, G.; Marbury, T.C.; Swan, S.K.; Lunde, N.M.; Bello, C.L. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J. Clin. Pharmacol., 2010, 50(4), 472-481.
[135]
Izzedine, H.; Etienne-Grimaldi, M.C.; Renee, N.; Vignot, S.; Milano, G. Pharmacokinetics of sunitinib in hemodialysis. Ann. Oncol., 2009, 20(1), 190-192.
[136]
Poprach, A.; Bortlicek, Z.; Melichar, B.; Lakomy, R.; Svoboda, M.; Kiss, I.; Zemanova, M.; Fiala, O.; Kubackova, K.; Coufal, O.; Pavlik, T.; Dusek, L.; Vyzula, R.; Buchler, T. Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. Eur. J. Cancer, 2015, 51(4), 507-513.
[137]
Josephs, D.; Hutson, T.E.; Cowey, C.L.; Pickering, L.M.; Larkin, J.M.; Gore, M.E.; Van Hemelrijck, M.; McDermott, D.F.; Powles, T.; Chowdhury, P.; Karapetis, C.; Harper, P.G.; Choueiri, T.K.; Chowdhury, S. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int., 2011, 108(8), 1279-1283.
[138]
Zastrow, S.; Froehner, M.; Platzek, I.; Novotny, V.; Wirth, M.P. Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis. Urology, 2009, 73(4), 868-870.
[140]
Weil, A.; Martin, P.; Smith, R.; Oliver, S.; Langmuir, P.; Read, J.; Molz, K.H. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin. Pharmacokinet., 2010, 49(9), 607-618.
[144]
Malik, S.M.; Maher, V.E.; Bijwaard, K.E.; Becker, R.L.; Zhang, L.; Tang, S.W.; Song, P.; Liu, Q.; Marathe, A.; Gehrke, B.; Helms, W.; Hanner, D.; Justice, R.; Pazdur, R.U.S. Food and Drug Administration approval: Crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin. Cancer Res., 2014, 20(8), 2029-2034.
[145]
De Jong, F.A.; Kitzen, J.J.; De Bruijn, P.; Verweij, J.; Loos, W.J. Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer Biol. Ther., 2006, 5(9), 1105-1110.
[146]
Slatter, J.G.; Schaaf, L.J.; Sams, J.P.; Feenstra, K.L.; Johnson, M.G.; Bombardt, P.A.; Cathcart, K.S.; Verburg, M.T.; Pearson, L.K.; Compton, L.D.; Miller, L.L.; Baker, D.S.; Pesheck, C.V.; Lord, R.S., III Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab. Dispos., 2000, 28(4), 423-433.
[147]
Sparreboom, A.; De Jonge, M.J.; De Bruijn, P.; Brouwer, E.; Nooter, K.; Loos, W.J.; Van Alphen, R.J.; Mathijssen, R.H.; Stoter, G.; Verweij, J. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin. Cancer Res., 1998, 4(11), 2747-2754.
[148]
Niemi, M.; Backman, J.T.; Kajosaari, L.I.; Leathart, J.B.; Neuvonen, M.; Daly, A.K.; Eichelbaum, M.; Kivisto, K.T.; Neuvonen, P.J. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther., 2005, 77(6), 468-478.
[149]
Kalliokoski, A.; Neuvonen, M.; Neuvonen, P.J.; Niemi, M. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br. J. Clin. Pharmacol., 2008, 66(6), 818-825.
[150]
Marbury, T.C.; Ruckle, J.L.; Hatorp, V.; Andersen, M.P.; Nielsen, K.K.; Huang, W.C.; Strange, P. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin. Pharmacol. Ther., 2000, 67(1), 7-15.
[151]
Zhao, P.; Vieira Mde, L.; Grillo, J.A.; Song, P.; Wu, T.C.; Zheng, J.H.; Arya, V. Berglund, E.G.; Atkinson, A.J., Jr.; Sugiyama, Y.; Pang, K.S.; Reynolds, K.S.; Abernethy, D.R.; Zhang, L.; Lesko, L.J.; Huang, S.M. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J. Clin. Pharmacol., 2012, 52(1)(Suppl.), 91S-108S.
[152]
Plum, A.; Muller, L.K.; Jansen, J.A. The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma. Methods Find. Exp. Clin. Pharmacol., 2000, 22(3), 139-143.
[153]
Tan, M.L.; Zhao, P.; Zhang, L.; Ho, Y.F.; Varma, M.V.S.; Neuhoff, S.; Nolin, T.D.; Galetin, A.; Huang, S.M. Use of physiologically based pharmacokinetic modeling to evaluate the effect of chronic kidney disease on the disposition of hepatic CYP2C8 and OATP1B drug substrates. Clin. Pharmacol. Ther., 2018, 105(3), 719-729.
[154]
Tan, M.L.; Yoshida, K.; Zhao, P.; Zhang, L.; Nolin, T.D.; Piquette-Miller, M.; Galetin, A.; Huang, S.M. Effect of chronic kidney disease on nonrenal elimination pathways: A systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clin. Pharmacol. Ther., 2018, 103(5), 854-867.
[155]
Schwenk, M.H.; Pai, A.B. Drug transporter function-Implications in CKD. Adv. Chronic Kidney Dis., 2016, 23(2), 76-81.
[156]
Yoshida, K.; Sun, B.; Zhang, L.; Zhao, P.; Abernethy, D.R.; Nolin, T.D.; Rostami-Hodjegan, A.; Zineh, I.; Huang, S.M. Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. Clin. Pharmacol. Ther., 2016, 100(1), 75-87.
[157]
Kim, A.H.; Yoon, S.; Lee, Y.; Lee, J.; Bae, E.; Lee, H.; Kim, D.K.; Lee, S.; Yu, K.S.; Jang, I.J.; Cho, J.Y. Assessment of hepatic cytochrome P450 3A activity using metabolic markers in patients with renal impairment. J. Korean Med. Sci., 2018, 33(53), e298.
[158]
Turpeinen, M.; Koivuviita, N.; Tolonen, A.; Reponen, P.; Lundgren, S.; Miettunen, J.; Metsarinne, K.; Rane, A.; Pelkonen, O.; Laine, K. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br. J. Clin. Pharmacol., 2007, 64(2), 165-173.
[159]
Hu, J.; Jing, H.; Lin, H. Sirtuin inhibitors as anticancer agents. Future Med. Chem., 2014, 6(8), 945-966.
[160]
Kozako, T.; Suzuki, T.; Yoshimitsu, M.; Arima, N.; Honda, S.; Soeda, S. Anticancer agents targeted to sirtuins. Molecules, 2014, 19(12), 20295-20313.
[161]
Martins, I.J. Induction of NAFLD with increased risk of obesity and chronic diseases in developed countries. Open J. Endocr. Metab. Dis., 2014, 4, 90-110.
[162]
Martins, I.J. Heat shock protein aggregation and chronic kidney disease. Res. Chronic Dis., 2018, 2(1), 42-44.
[163]
Martins, I.J. Increased risk for obesity and diabetes with neurodegeneration in developing countries. J. Mol. Genet. Med., 2018, S1, 2-8.
